Jon has stated a few times that there are not many companies in the world with our pipeline. Treating 5 rare neuro conditions would be the envy of many bio's. Given the robust results of Trof the Board are very bullish on NNZ-2591, and rightly so. I dont think a US $850m offer ($8.78AUD a share based on .75 FX) would be accepted. It would be considered but ultimately i think it would be rejected and i am basing that on the offer coming before P2 results for NNZ-2591.
Ann: Q4 2021 quarterly activity and cash flow report, page-40
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.91 |
Change
-0.050(0.39%) |
Mkt cap ! $1.602B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.02 | $12.70 | $1.043M | 81.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 202 | $12.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.91 | 395 | 8 |
View Market Depth
| Last trade - 11.04am 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |